Beijing Kangairuihao Biotechnology

Beijing Kangairuihao Biotechnology is a clinical-stage Chinese biotechnology company specializing in the development of innovative cell therapies for the treatment of solid tumors. Founded in 2014, the company focuses on autologous and allogeneic Natural Killer (NK) cell and T cell technologies, leveraging its proprietary K-NK and K-T expansion platforms. Its lead programs are currently undergoing clinical trials for various oncology indications, including lung and liver cancers. Kangairuihao aims to address the limitations of current cancer treatments by enhancing the anti-tumor activity and persistence of immune cells. The company is headquartered in Beijing and maintains advanced R&D and GMP-compliant manufacturing facilities.